8-Day Rally Sends Quince Therapeutics Stock Up 105%
Quince Therapeutics (QNCX) stock hit day 8 of a continuous streak of days with gains, with cumulative gains over this period amounting to a 105% return. The company has gained about $83 Mil in value over the last 8 days, with its current market capitalization at about $161 Mil. The stock remains 84.5% above its value at the end of 2024. This compares with year-to-date returns of 15.8% for the S&P 500.
Quince Therapeutics is experiencing a significant uplift, fueled by a positive independent safety review of its pivotal Phase 3 NEAT trial and mounting anticipation for topline results in Q1 2026. Strategic investor events in December are further sharpening focus on the rare disease specialist’s pipeline and commercialization plans, drawing substantial market interest.
What is the point? Momentum often precedes conviction. A multi-day win streak can signal growing investor confidence or spark follow-on buying. Tracking such trends can help you ride the strength, or prepare for a well-timed entry if momentum fades.For quick background, QNCX is a clinical-stage biopharmaceutical company developing therapeutics for Alzheimer’s and degenerative diseases, with a lead oral brain-penetrating gingipain inhibitor drug candidate.
Comparing QNCX Stock Returns With The S&P 500
The following table summarizes the return for QNCX stock vs. the S&P 500 index over different periods, including the current streak:
| Return Period | QNCX | S&P 500 |
|---|---|---|
| 1D | 29.2% | 0.7% |
| 8D (Current Streak) | 105.4% | 1.2% |
| 1M (21D) | 99.4% | -1.1% |
| 3M (63D) | 124.0% | 4.8% |
| YTD 2025 | 84.5% | 15.8% |
| 2024 | 78.1% | 23.3% |
| 2023 | 64.7% | 24.2% |
| 2022 | -94.9% | -19.4% |
Gains and Losses Streaks: S&P 500 Constituents
There are currently 136 S&P constituents with 3 days or more of consecutive gains and 8 constituents with 3 days or more of consecutive losses.
| Consecutive Days | # of Gainers | # of Losers |
|---|---|---|
| 3D | 20 | 7 |
| 4D | 94 | 0 |
| 5D | 14 | 0 |
| 6D | 3 | 0 |
| 7D or more | 5 | 1 |
| Total >=3 D | 136 | 8 |
Key Financials for Quince Therapeutics (QNCX)
Last 2 Fiscal Years:
| Metric | FY2023 | FY2024 |
|---|---|---|
| Revenues | $0 | $0 |
| Operating Income | $-27.1 Mil | $-36.2 Mil |
| Net Income | $-31.4 Mil | $-56.8 Mil |
Last 2 Fiscal Quarters:
| Metric | 2025 FQ1 | 2025 FQ2 |
|---|---|---|
| Revenues | $0 | $0 |
| Operating Income | $-12.9 Mil | $-9.9 Mil |
| Net Income | $-15.0 Mil | $-16.0 Mil |
While QNCX stock looks attractive given its winning streak, investing in a single stock without detailed, thorough analysis can be risky. The Trefis High Quality (HQ) Portfolio, with a collection of 30 stocks, has a track record of comfortably outperforming its benchmark that includes all 3 — the S&P 500, S&P mid-cap, and Russell 2000 indices. Why is that? As a group, HQ Portfolio stocks provided better returns with less risk versus the benchmark index; less of a roller-coaster ride, as evident in HQ Portfolio performance metrics.